Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

1,213
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

468
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

A RANDOMIZED, DOUBLE-BLIND, PLACEBO - CONTROLLED STUDY OF SAFETY OF THE ADJUNCTIVE SAFFRON ON SEXUAL DYSFUNCTION INDUCED BY A SELECTIVE SEROTONIN REUPTAKE INHIBITOR

Pages

  121-130

Abstract

 Background: Recent studies have indicated potential of SAFFRON for applying in a wide variety of diseases such as psychiatric and neurologic disorders. The concurrent use of SAFFRON with SSRIs can lead to reducing the dose of SSRIs. SAFFRON at a dose of 200 mg may change some hematological and biochemical parameters.Objective: The goal of this trial was to assess the safety of concomitant administration of SAFFRON and SSRI in patients with major depressive disorder (MDD).Methods: Twenty adult outpatients between 18 to 55 years-old with the diagnosis of MDD who were receiving an SSRI for at least 1 month prior to the initiation of the study entered this double-blind trial. They were randomly assigned to receive capsule of SAFFRON (15 mg twice daily) or placebo. Some laboratory parameters were measured at baseline and week 4 of the study.Other side effects checked on a prepared list of side effects, were systematically recorded throughout the study at baseline and on a weekly basis.Results: SAFFRON as an add-on medication to SSRIs for 4 weeks did not cause any statistically significant changes in laboratory parameters including AST, ALT, ALP, BUN, Cr., FBS, TG, TC, WBC, RBC, Hgb, Ht, PT, INR, and Pl count.Conclusion: This preliminary study provides safety evidences of concurrent intake of SAFFRON and SSRI.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    MANSOORI, P., AKHONDZADEH, S., RAISI, F., GHAELI, P., JAMSHIDI, A.H., NASEHI, A.A., SOHRABI, H., & SAROUKHANI, S.. (2011). A RANDOMIZED, DOUBLE-BLIND, PLACEBO - CONTROLLED STUDY OF SAFETY OF THE ADJUNCTIVE SAFFRON ON SEXUAL DYSFUNCTION INDUCED BY A SELECTIVE SEROTONIN REUPTAKE INHIBITOR. JOURNAL OF MEDICINAL PLANTS, 10(37), 121-130. SID. https://sid.ir/paper/572735/en

    Vancouver: Copy

    MANSOORI P., AKHONDZADEH S., RAISI F., GHAELI P., JAMSHIDI A.H., NASEHI A.A., SOHRABI H., SAROUKHANI S.. A RANDOMIZED, DOUBLE-BLIND, PLACEBO - CONTROLLED STUDY OF SAFETY OF THE ADJUNCTIVE SAFFRON ON SEXUAL DYSFUNCTION INDUCED BY A SELECTIVE SEROTONIN REUPTAKE INHIBITOR. JOURNAL OF MEDICINAL PLANTS[Internet]. 2011;10(37):121-130. Available from: https://sid.ir/paper/572735/en

    IEEE: Copy

    P. MANSOORI, S. AKHONDZADEH, F. RAISI, P. GHAELI, A.H. JAMSHIDI, A.A. NASEHI, H. SOHRABI, and S. SAROUKHANI, “A RANDOMIZED, DOUBLE-BLIND, PLACEBO - CONTROLLED STUDY OF SAFETY OF THE ADJUNCTIVE SAFFRON ON SEXUAL DYSFUNCTION INDUCED BY A SELECTIVE SEROTONIN REUPTAKE INHIBITOR,” JOURNAL OF MEDICINAL PLANTS, vol. 10, no. 37, pp. 121–130, 2011, [Online]. Available: https://sid.ir/paper/572735/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top